Top Markets
Coin of the day
Maxigen Biotech Inc. Maxigen Biotech Inc.

Maxigen Biotech Inc.

1783
Kedudukan dalam Saham #21088
Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development,... Maxigen Biotech Inc. (MBI) is a company dedicated to the research, development, production, and global commercialization of advanced biomedical and skincare solutions. Its extensive biomedical portfolio includes various orthopedic products such as Formagraft, a bone graft substitute, and Formasetin, a bone void filler. For intra-articular applications in orthopedics, MBI markets injections under the names ArtiAid, ArtiAid Plus, and ArtiBest. The company's offerings also span both orthopedic and dental fields, featuring Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental graft. Specifically for dental use, MBI provides FormaAid, a collagen membrane, and the E-TECH DENTISTAR II sterilizer and disinfectant. Furthermore, HealiAid, a collagen wound dressing product, serves dental and general wound care purposes. MBI also manufactures ophthalmic viscoelastic devices, known as ViscAid, PreviscAid, and BiVisc, and produces Formaderm, a dermal filler injection utilized in plastic surgery. Beyond its medical devices, Maxigen Biotech Inc. offers a comprehensive line of skincare products. This array includes masks for the face, neck, body, and limbs, alongside make-up removers, cleansers, exfoliants, toners, essences, men's grooming items, sunscreens, and specialized body, hand, and foot care formulations. Maxigen Biotech Inc. was established in 1998 and operates from its main office in Taoyuan City, Taiwan.
Harga Saham
$1.28
Disegerakkan terakhir: 2026-08-21
Modal Pasaran
$115.23M
Perubahan (1 hari)
-0.25%
Perubahan (1 tahun)
-10.17%
Negara
TW
Perdagangan Maxigen Biotech Inc. (1783)

Kategori

Pendapatan untuk Maxigen Biotech Inc. (1783)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Maxigen Biotech Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Maxigen Biotech Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$3.81B -
US
$4.11B -
FR
- -
JP
$1.59B -
US
- -
CH